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The selection of candidates for BRCA germline mutation testing is an important clinical issue yet it remains a significant challenge. A
number of risk prediction models have been developed to assist in pretest counselling. We have evaluated the performance and the
inter-rater reliability of four of these models (BRCAPRO, Manchester, Penn and the Myriad-Frank). The four risk assessment models
were applied to 380 pedigrees of families who had undergone BRCA1/2 mutation analysis. Sensitivity, specificity, positive and negative
predictive values, likelihood ratios and area under the receiver operator characteristic (ROC) curve were calculated for each model.
Using a greater than 10% probability threshold, the likelihood that a BRCA test result was positive in a mutation carrier compared
to the likelihood that the same result would be expected in an individual without a BRCA mutation was 2.10 (95% confidence
interval (CI) 1.66–2.67) for Penn, 1.74 (95% CI 1.48–2.04) for Myriad, 1.35 (95% CI 1.19–1.53) for Manchester and 1.68 (95% CI
1.39–2.03) for BRCAPRO. Application of these models, therefore, did not rule in BRCA mutation carrier status. Similar trends were
observed for separate BRCA1/2 performance measures except BRCA2 assessment in the Penn model where the positive likelihood
ratio was 5.93. The area under the ROC curve for each model was close to 0.75. In conclusion, the four models had very little impact
on the pre-test probability of disease; there were significant clinical barriers to using some models and risk estimates varied between
experts. Use of models for predicting BRCA mutation status is not currently justified for populations such as that evaluated in the
current study.
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Germline mutations in BRCA1 and BRCA2 confer an estimated 65
and 45% cumulative lifetime risk of developing breast cancer, and
an ovarian cancer risk of 39 and 11%, respectively (Antoniou et al,
2003). Identification of these individuals before they present
with cancer is important since prophylactic surgery can reduce
morbidity and mortality in these individuals (Struewing et al, 1995;
Rebbeck et al, 1999; Hartmann et al, 1999; Hartmann et al, 2001;
Meijers-Heijboer et al, 2001; Kauff et al, 2002; Rebbeck et al, 2004).
Unfortunately, genetic testing is expensive, family history of breast
cancer is common and BRCA mutations are rare (Ford et al, 1994;
Peto et al, 1999; Antoniou et al, 2002). A triage tool to identify
those families most likely to benefit from germline testing would,
therefore, be very useful. Like most countries (summarized by
Nelson et al, 2005), Australia has developed guidelines (NBCC
Genetics Working Group, 2000) for the referral of individuals to a
family cancer clinic for counselling and further evaluation. Under
these guidelines, full BRCA1/2 mutation screening is usually
restricted to individuals affected by breast or epithelial ovarian
cancer, and whose family history as a whole satisfies a ‘potentially
high-risk category’ (NBCC Genetics Working Group, 2000; Nelson
et al, 2005). The prevalence of germline BRCA mutations in such
high-risk families is estimated at 3.4–15.5% (Frank et al, 2002;
Huang et al, 2002; Antoniou et al, 2003; Myriad, 2004; Nelson et al,
2005). These low figures have led to the development of models
that can more accurately assess the pre-test probability of
identifying a BRCA1/2 germline mutation (Couch et al, 1997;
Parmigiani et al, 1998; Berry et al, 2002; Frank et al, 2002; Evans
et al, 2004). Mendelian models like BRCAPRO (Parmigiani et al,
1998; Berry et al, 2002) evaluate the probability that an individual
is a gene mutation carrier, while other models such as
Penn (Couch et al, 1997), Manchester (Evans et al, 2004) and
Frank-Myriad (Frank et al, 2002) determine the likelihood of
identifying a mutation on the basis of known family history.
Although the performance of some of these models has been
previously examined, it is perhaps telling that no single model
has been universally adopted. Previous model validation studies
have considered only a subset of the available models, have not
compared the results with germline testing, and have not
considered the barriers to the use of models in clinical practice
(Berry et al, 2002; Euhus et al, 2002; de la Hoya et al, 2003; Marroni
et al, 2004; James et al, 2006; Barcenas et al, 2006).
This study sought to compare the ability of four models
(BRCAPRO, Manchester, Penn and the Myriad-Frank) to deter-
mine the likelihood of finding a BRCA gene mutation in at-risk
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germline testing.
METHODS
Patient cohort
Family cancer clinics at St Vincent’s and Westmead Hospitals,
Sydney, provided pedigrees of families who had undergone
BRCA1/2 mutation analysis in the period 1998–2004. BRCA1/2
testing was performed using the DNA of an affected individual,
usually the youngest living available affected person, or an obligate
gene mutation carrier. For the purposes of the study, this
individual was defined as the proband. Families in which no
affected individuals were available for BRCA1/2 testing were not
included in the study. To be eligible for germline testing, at least
one unaffected family member must have had a life time risk of
breast cancer of 1:4 or greater as defined by the Australian
National Breast Cancer (NBCC) guidelines (NBCC Genetics
Working Group, 2000). This included individuals with at least
two first- or second-degree relatives on one side of the family
diagnosed with breast or ovarian cancer, together with additional
features on the same side of the family. These features included
an additional relative with breast or ovarian cancer; breast
cancer diagnosed before the age of 40 years, ovarian cancer
before 50 years, bilateral breast cancer, breast and ovarian cancer
in the same woman, Jewish ancestry or breast cancer in a male
relative.
Each pedigree was de-identified, with only the sex, birthday,
date of death, type of cancer and age at diagnosis retained for the
analysis. Not all cancers could be verified because of the
requirement for client consent in Australia. Pedigrees were viewed
with Progeny software v5.4.05 (Progeny Software, LLC, South
Bend, IN, USA). Furthermore, families of Ashkenazi Jewish
ancestry were not included in this study. This study was approved
by the St Vincents Hospital Human Research Ethics Committee.
Use of models to identify mutation carriers
Each of the four risk assessment models (Manchester (Evans et al,
2004; Evans et al, 2005), Myriad (Frank et al, 2002), Penn (Couch
et al, 1997) and BRCAPRO (Parmigiani et al, 1998; Berry et al,
2002)) were applied to each pedigree by two investigators (HK and
RWi). All models except Myriad allow calculations for combined
BRCA mutation status, as well as BRCA1 and BRCA2 indepen-
dently. Risk assessments were based on the proband, and maternal
or paternal inheritance was assessed using the Progeny program
(Progeny Software, LLC, South Bend, IN, USA). If the potential
carrier side was not obvious, the assessments were conducted for
both paternal and maternal relatives and the highest score was
included in the analysis. As data on some pedigrees was
ambiguous or incomplete, prespecified rules were used for the
entry of information into each model (Table 1). Determination of
mutation likelihood using the Manchester model was performed
by assigning a score on the basis of malignancy type and age
of diagnosis (Evans et al, 2004). Scores obtained do not equate
directly to probabilities; however, the authors suggest that a cut-
off score of 10 points for BRCA1 and BRCA2 separately, or a
combined score of 15 points correspond to an approximate
mutation probability of 10% (Evans et al, 2004; Evans et al, 2005).
The Myriad model was applied using on-line tables (Myriad, 2004)
and an on-line questionnaire was used to obtain independent
probabilities for BRCA1 and BRCA2 mutations using the Penn
model (University of Pennsylvania Abramson Cancer Center,
2005). The latter model requires the presence of breast cancer in
the family lineage and thus six families with only ovarian cancer
could not be analysed. The overall chance of a mutation in either
BRCA1 or BRCA2 was calculated as the probability of mutation in
BRCA1 plus the probability of mutation in BRCA2 assuming there
was no mutation in BRCA1. For the BRCAPRO model, carrier
probabilities were calculated by entering information on the
proband’s first- and second-degree relatives into CancerGene
software (CaGene version 3.3, supplied by Assistant Professor D
Euhus, UT Southwestern Medical Center at Dallas, Texas, USA).
Mutation screening for BRCA1 and BRCA2
The extent to which BRCA1/2 were screened reflects the
availability of testing methodologies over the study period. Full
DNA sequence analysis of BRCA1/2 together with a screen for the
BRCA1 exon 13 duplication (common in families of British
descent) (Puget et al, 1999) was used as the minimum testing
regime in 89 families. Mutation analysis on the remaining 291
families was performed by a screening strategy that involved the
use of a number of different techniques. The protein truncation
test (PTT) was performed for exon 11 of BRCA1 and exons 10, 11
and 27 of BRCA2. This test covers 65% of the coding region for
each gene and identifies the most common types of pathogenic
mutation in BRCA1/2 (Garvin, 1998). Sequence analysis or
heteroduplex analysis of exons 2 and 20 of BRCA1 using either
polyacrylamide gel electrophoresis or denaturing high-perfor-
mance liquid chromatography were used to detect nonsense,
frameshift and missense mutations within these exons. All samples
were screened for the BRCA1 duplication exon 13 mutation
and a subset of 125 families from the entire cohort were also
screened for rare large genomic rearrangements in BRCA1
using multiplex ligation-dependent probe amplification (MLPA)
(Woodward et al, 2005).
BRCA1/2 sequence variants of uncertain clinical significance
were identified in nine cases and these families were excluded from
the analysis; however, families with nondeleterious, common
polymorphisms were included in the no-mutation group.
Table 1 Conventions used for interpreting ambiguous pedigrees
Issue Resolution
Applicable
model
Half siblings Considered full siblings M, P, B, My
Age of cancer diagnosis unknown Assigned lowest age possible consistent with current age M
Bilateral breast cancer Counted as two different cases M, My
Bilateral ovarian cancer Counted as one case M, P, B, My
Age of living relative unknown Estimated as 25 years younger than parent or 2 years difference from sibling B
Age of death not specified Estimated as 70 years or approximated from age of death of siblings B
Malignancy age 470 years, age of death unknown Death estimated as 2 years post diagnosis if cancer is the cause of death B
Death in infancy Age of death recorded as 1 year B
Age of cancer diagnosis unknown Estimated as 2 years before death for deceased relatives and 2 years younger than
current age for living relatives
B
M¼Manchester, P¼Penn, B¼BRCAPRO, My¼Myriad.
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sStatistical methods
All generated scores were analysed using SPSS statistical software
V13.0 (SPSS Inc., Chicago, IL, USA). Sensitivity, specificity,
positive and negative predictive values, and positive and negative
likelihood ratios were calculated for each risk model at the 10%
threshold. For the Manchester model, this threshold corresponded
with a cutoff score of 10 points for BRCA1 and BRCA2 separately,
and a score of 15 points for the combined model. The positive
likelihood ratio of a model was calculated as the proportion of
individuals with a BRCA1/2 mutation who have a model probability
10% or greater divided by the proportion of individuals without a
mutation who have a model probability 410%. Similarly, the
negative likelihood ratio was calculated as the ratio of the
proportion of individuals with a BRCA1/2 mutation who have a
model probability o10% to the proportion of individuals without a
mutation who have a model probability o10%. Receiver operator
characteristics (ROC) curves were constructed by plotting the
sensitivity (or true positive fraction) against 1 minus specificity (or
false positive fraction) for all possible values of the mutation
probability. The area under the ROC curve (C-statistic) was
calculated as a measure of the accuracy of the model for
discriminating between mutation carriers and those without a
BRCA mutation. It represents the fraction of all probands with
identified family mutations that have a detection probability higher
than a proband with no mutation identified in the family. The k
scores were used to assess the measure of agreement between 100
independent risk calculations from 100 pedigrees chosen at random.
In this analysis, a score of 0–0.2 describes slight, 0.2–0.4 fair,
0.4–0.6 moderate, 0.6–0.8 substantial and over 0.8 almost perfect
agreement (Koch et al,1 9 7 7 ) .
RESULTS
Proportion of positive BRCA tests varied according to
carrier probability
The study cohort included pedigrees from 380 families, of whom
52 (13.7%) carried deleterious mutations in either BRCA1 (34
subjects) or BRCA2 (18 subjects). The mutation frequency was
higher (22.5%) in individuals subjected to complete DNA
sequencing of BRCA1/2 (20 of 89 individuals) compared with
those in whom sequencing had not been performed (11%, 32 of
291 subjects).
A total of 45 different mutations were recorded among the BRCA
mutation positive families, whereas duplication of BRCA1 exon 13
occurred in a further five families. The mean carrier probabilities
for mutation-positive individuals were 53% using BRCAPRO, 26%
for Myriad and 32% using the Penn model. The probabilities for
mutation-negative individuals were 24, 14, and 12%, respectively.
The mean score for mutation-positive individuals using the
Manchester model was 37; the mean score for mutation-negative
individuals was 21. All models showed a relationship between the
carrier probability and the proportion of positive tests (Table 2).
Discrimination of BRCA mutation carriers from
noncarriers
Table 3 shows the sensitivity, specificity, positive and negative
predictive values for each risk model at the 10% threshold. The
negative predictive value of all four models was remarkably
consistent (range¼0.93–0.96) in that only 4–6% of families
assigned a mutation probability of 10% or less actually carried a
Table 2 The proportion of BRCA mutation carriers according to carrier probability as determined by the four combination models
Category of carrier probability (%)
a
o10 10–20 20–40 40–60 60–80 480
Manchester 0/19(0.0%) 12/176(6.8%) 22/147(15.0%) 12/31(38.7%) 2/3(66.7%) 4/4(100%)
BRCAPRO 12/190(6.3%) 6/48(12.5%) 4/36(11.1%) 3/24(12.5%) 9/39(27.3%) 18/43(41.9%)
Myriad 8/176(4.6%) 14/115(12.2%) 17/61(27.9%) 13/26(50.0%) 0/2(0.0%) N/A
Penn 16/232(6.9%) 13/74(17.6%) 8/37(21.6%) 2/12(16.7%) 6/8(75.0%) 7/11(63.6%)
Six families with only ovarian cancer could not be analysed by the Penn model. N/A¼not applicable.
aScore, rather than probability, for Manchester model.
Table 3 Performance measures for each model at the 10% threshold
Proportion of carriers by model probability (%) Test parameters at 10% threshold (95% CI)
o10 X10% Sensitivity Specificity PPV NPV
Combined
Manchester 6/119 46/261 0.89(0.77,0.95) 0.35(0.30,0.40) 0.18(0.14,0.23) 0.95(0.89,0.98)
BRCAPRO 12/190 40/190 0.77(0.64,0.86) 0.54(0.49,0.60) 0.21(0.16,0.27) 0.94(0.89,0.96)
Myriad 8/176 44/204 0.85(0.73,0.92) 0.51(0.46,0.57) 0.22(0.17,0.28) 0.96(0.91,0.98)
Penn 16/232 36/142 0.69(0.56,0.80) 0.67(0.62,0.72) 0.25(0.19,0.33) 0.93(0.89,0.96)
BRCA1
Manchester 4/187 30/193 0.88(0.73,0.95) 0.53(0.48,0.58) 0.16(0.11,0.21) 0.98(0.95,0.99)
BRCAPRO 7/225 27/155 0.79(0.63,0.90) 0.63(0.58,0.68) 0.17(0.12,0.24) 0.97(0.94,0.99)
Penn 14/281 20/93 0.58(0.42,0.74) 0.79(0.74,0.83) 0.22(0.14,0.31) 0.95(0.92,0.97)
BRCA2
Manchester 6/189 12/191 0.67(0.44,0.84) 0.51(0.45,0.56) 0.06(0.04,0.11) 0.97(0.93,0.99)
BRCAPRO 12/308 6/72 0.33(0.16,0.56) 0.82(0.78,0.85) 0.08(0.04,0.17) 0.96(0.93,0.98)
Penn 12/348 6/26 0.33(0.16,0.56) 0.94(0.92,0.96) 0.23(0.11,0.42) 0.97(0.94,0.98)
PPV¼positive predictive value, how likely the patient is to have a mutation given that the model predicts carrier status. NPV¼ negative predictive value, how likely mutation is
not present, given that the model does not predict mutation status. A Manchester score of 10 for BRCA1 and BRCA2 or a combined score of 15 corresponds with a mutation
probability of 10% (Evans et al, 2004).
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smutation in BRCA1 or BRCA2 (Table 3). Given the relatively low
prevalence of BRCA mutations in the study population, it is not
surprising that the positive predictive value at the 10% threshold
was low (range¼0.18–0.25). The predictive value improved as the
threshold probability was increased; however, 58% of probands
assigned an 80% or greater mutation probability using BRCAPRO
did not have a mutation detected (Table 2). All probands with a
score of 80 or more according to the Manchester model carried a
mutation. The likelihood that the model probability was 410% in
a mutation carrier was 2.10 (95% CI 1.66–2.67) for Penn, 1.74
(95%CI 1.48–2.04) for Myriad, 1.35 (95% CI 1.19–1.53) for
Manchester and 1.68 (95% CI 1.39–2.03) for BRCAPRO. Applica-
tion of these models, therefore, does not rule in BRCA mutation
carrier status. The negative likelihood ratios were consistently
greater than 0.1 (BRCAPRO 0.43, Manchester 0.34, Myriad 0.30
and Penn 0.46), which indicated that the models are also unable to
rule out mutation carrier status. The post-test probability for
mutation carrier status (calculated by multiplying pre-test odds of
disease by the positive or negative likelihood ratio) is shown in
Figure 1. It is apparent that the estimated pre-test probability of a
mutation is not significantly altered by calculating the mutation
risk estimate using each of the models. For example, a prediction
of a germline mutation for the Penn model would change an
individual’s pre-test mutation probability from 40 to 58%, whereas
using the Manchester model it would increase from 40 to 47%.
The accuracy of the four models was also compared by
examining the areas under the ROC curve (Figure 2 and Table 4).
A model that correlates perfectly with BRCA mutation status
would have an area under the curve of 1.0 while an area of 0.5
indicates that the model has no discriminatory value. Using the
scores for detecting either a BRCA1 or BRCA2 mutation, the area
under the curve for each model was close to 0.75 (Table 4). By this
measure, the models were equal in their ability to discriminate
between mutation carrying and noncarrying probands.
To evaluate the possibility that the mutation-testing strategy
influences the performance of the models, we stratified the data
according to type of gene sequencing results. Although the
frequency of mutation carriers was higher in the group tested by
BRCA1/2 sequencing, the models were found to perform similarly
for those with and without complete DNA sequencing results.
While positive predictive values of models tended to be higher for
those with complete DNA sequencing, there were no significant
differences in mean model scores or probabilities, sensitivity,
specificity, predictive values, likelihood ratios and C-statistics
(data not presented).
Differentiating mutations in BRCA1 and BRCA2
The Manchester, BRCAPRO and Penn models allow separate
calculations of the probability of BRCA1 and BRCA2 mutations
(Tables 3 and 5). The positive likelihood ratios for BRCA1
mutation carriers were 2.74 (95% CI 1.94–3.88) for Penn, 1.87
(95% CI 1.59–2.21) for Manchester and 2.15 (95% CI 1.72–2.67)
for BRCAPRO. The negative likelihood ratios were 0.52, 0.22 and
0.36, respectively. The Penn model could potentially be used to
rule in BRCA2 mutations, in that the positive likelihood ratio was
5.93 (95% CI 2.72–12.94) although the negative likelihood ratio
0.8
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Figure 1 Post-test probability for mutation carrier status is shown for
each model using the positive and negative likelihood ratios.
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Figure 2 Receiver operator characteristics (ROC) curves for models comprising BRCA1, BRCA2 and the combination. Diagonal segments are produced
by ties.
Table 4 Area under the ROC curve (C-statistics) for each model
95% confidence interval
Test result variable C-statistics Lower bound Upper bound
BRCA1 models
Manchester 0.808 0.738 0.879
BRCAPRO 0.802 0.731 0.874
Penn 0.808 0.740 0.876
BRCA2 models
Manchester 0.660 0.523 0.797
BRCAPRO 0.626 0.500 0.752
Penn 0.703 0.569 0.838
Combination
Manchester 0.759 0.688 0.831
BRCAPRO 0.743 0.672 0.814
Myriad 0.753 0.680 0.827
Penn 0.757 0.686 0.827
ROC¼receiver operator characteristic.
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swas unacceptably high at 0.71 (95% CI 0.51–0.98). The Manchester
and BRCAPRO had likelihood ratios around 1, indicating that
these models provided no additional information in determining
BRCA2 mutation carrier status.
A comparison of the respective ROC curves shows that the
Manchester model, BRCAPRO and Penn performed similarly for
BRCA1, but that BRCAPRO was the least accurate model for
BRCA2 identification (Figure 2, Table 4). The proportions of
BRCA1 and 2 mutation carriers at each threshold for the
Manchester, BRCAPRO and Penn models are shown in Table 5.
Validation of risk calculation estimates
Given the inherent ambiguities in interpreting pedigrees, two of
the investigators (HK and RWi) specified rules for dealing with
various clinical scenarios (see methods and Table 1). At the
completion of the study, a k score of mutation-risk estimates using
the models was determined for 100 randomly selected pedigrees
(25 cases for each risk model). Overall, the k score was 0.82
reflecting excellent agreement between observers when calculating
the mutation risk for each proband. The measure of agreement
differed between models in that perfect agreement was noted for
Penn (k¼1.0) and Manchester (k¼0.932), whereas only sub-
stantial agreement was found for Myriad (k¼0.714) and for
BRCAPRO (k¼0.60). The areas of disagreement in applying the
BRCAPRO model were related to clinical judgment on choice of
proband, estimation of age of relatives, and inclusion of maternal
and paternal relatives.
DISCUSSION
In this study we used the family histories of a large tested cohort,
some with known BRCA germline mutations, to evaluate the
clinical effectiveness of four risk prediction models for BRCA
mutations. Estimation of pre-test mutation probability is an
important clinical issue, particularly in view of the expense, legal
implications and other difficulties associated with ambiguous
germline BRCA testing results. Germline testing is currently
recommended solely on the basis of clinical suspicion, yet even
within this group of patients few will harbour a mutation (13% in
the current study). While prediction models (Euhus, 2001;
Domchek et al, 2003) offer an opportunity to improve clinical
decision-making, to be effective in clinical practice they must be
practical as well as accurate. Our study highlighted certain aspects
of the models, which are likely to detract from their effective use in
family cancer clinics. The Manchester model (Evans et al, 2004)
and the Myriad mutation prevalence tables (Myriad, 2004) did not
require computer access and were extremely rapid methods of
assessing risk. Like most empiric models, the risk estimates relied
on the ‘number of cases per family’, yet the definition of a family
can be highly subjective. For instance, large pedigrees with many
elderly female subjects with breast cancer generated a cumulative
score above 10% using the Manchester model. On the other hand,
the Myriad tables only allowed inclusion of a maximum of three
members of the family, including the patient. Other disconcerting
features of the Myriad model were that breast cancers diagnosed
above 50 years were ignored, whereas for those diagnosed before
50 years there was no stratification according to the age of
diagnosis. Further deficiencies included the equal weighting given
to male and female breast cancers and the inability to input
bilateral breast cancer or other tumours associated with BRCA1/2
mutation, namely prostate and pancreatic cancers (Lynch et al,
1999; Tulinius et al, 2002; Liede et al, 2004).
Both the Penn model and BRCAPRO required computer access.
In the case of BRCAPRO, the time taken to enter family trees was a
major impediment to routine use. BRCAPRO only incorporates
first- and second-degree relatives and therefore cousins of the
proband who are affected with cancer will not be used to generate a
probability score unless the counselor changes the proband. This
scenario was in part responsible for the low k scores associated
with the use of BRCAPRO. The on-line Penn model was a very
rapid and efficient mode of calculating not only the individual but
also the family’s probability of carrying a BRCA1/2 mutation. The
model also provided question prompts with helpful explanatory
comments; this feature significantly reduced the chance of
disagreement between the independent risk assessors. Unfortu-
nately, the Penn model also restricted questions to three
generations, and did not include ovarian cancer only families or
mother–daughter ovarian–breast cancer inheritance patterns.
In comparing the accuracy of the models, we found that they
had an equal ability to discriminate between mutation carrying
and noncarrying probands (C-statistic 0.743–0.759 for combined
analysis using the ROC curves) when considering the entire range
of possible test thresholds. These results are highly comparable to
those of an Italian study of BRCA mutation carriers where risk was
assessed using the Myriad tables, BRCAPRO and an old version of
the Penn model (Marroni et al, 2004). The initial report of the
Manchester model claimed superiority over BRCAPRO on the
basis of a larger area under the ROC curve (0.772 vs 0.596) (Evans
et al, 2004). We were unable to confirm these findings and note
that the area under the curve reported by Evans et al for BRCAPRO
was considerably lower than that found in the current study as well
as a number of other studies (Euhus et al, 2002; Marroni et al,
2004). The source of these discrepancies may relate to the
limitations of comparing a scoring system (Manchester) with
probability calculations (BRCAPRO).
Although the area under the ROC curves was comparable
between models, this does not mean that they are equally accurate
in predicting germline mutation status at the well-accepted 10%
Table 5 The proportion of BRCA1 and BRCA2 mutation carriers according to carrier probability as determined by Manchester, BRCAPRO and Penn
Category of carrier probability (%)
a
o10 10–20 20–40 40–60 60–80 480
BRCA1
Manchester 4/187(2.1%) 15/150(10.0%) 12/39(30.8%) 3/3(100.0%) 0/1(0.0%) N/A
BRCAPRO 7/225(3.1%) 4/43(9.3%) 3/37(8.1%) 3/26(11.5%) 6/25(24.0%) 11/24(45.8%)
Penn 14/281(5.0%) 4/42(9.5%) 4/25 (16.0%) 1/7(14.3%) 5/8(62.5%) 6/11(54.6%)
BRCA2
Manchester 6/189(3.2%) 6/152(3.9%) 5/37(13.5%) 0/1(0.0%) 1/1(100.0%) N/A
BRCAPRO 12/308(3.9%) 1/35(2.9%) 2/19(10.5%) 1/9(11.1%) 2/7(28.6%) 0/2(0.0%)
Penn 12/348(3.5%) 5/20(25.0%) 1/6(16.7%) N/A N/A N/A
N/A¼not applicable.
aScore, rather than probability, for Manchester model.
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such a comparison and also provides an assessment of the value of
the models in relation to other tools. Penn was the most
discriminatory model, in that individuals with BRCA mutation
were twice as likely to have a positive prediction as those without a
germline mutation. In contrast, the Manchester model had a
ratio closer to unity indicating that it is unhelpful in clinical
decision-making. In other areas of medicine, likelihood ratios
greater than 5 are generally a prerequisite for the adoption of a
clinical test or procedure. By way of comparison, the positive
likelihood ratio for mammography is 14 (Kerlikowske et al, 1995),
for bedside cardiac-specific troponin T 6.3 (Antman et al, 1995)
and for ultrasonography for deep venous thrombosis 47.8 (Wells
et al, 2000).
The separate BRCA1/2 performance measures for Manchester,
BRCAPRO and Penn displayed similar trends to the combined
values, with the only exception being the use of Penn for
assessment of BRCA2 risk, where the positive likelihood ratio
was 5.9. A positive result in Penn for BRCA2 mutation should
confidently warrant a mutation screen.
Overall, our study suggests that routine use of Penn, Manche-
ster, BRCAPRO or Myriad for predicting BRCA mutation status in
clinical practice is not currently justified. Furthermore, as the
performance of the models was not influenced by the type of
mutation testing, we should consider other sources of error. Risk
models are developed and applied on the basis of pedigrees
constructed from clinical histories. Yet, these histories are
themselves often inaccurate in that cancer verification is often
impossible and age at diagnosis is frequently an estimate. We have
shown that even where prespecified criteria are established to
address the nuances of various patient scenarios, the expert
counselor may still interpret the pedigree in a way that alters the
risk estimates. BRCA germline mutation testing represents a
further source of significant error. The true prevalence of BRCA
mutations is often underestimated because of the limitations of
molecular testing (sensitivity of molecular techniques 70%) (Eng
et al, 2001). Furthermore, models are often derived on the basis of
mutation testing results from one uncharacterised individual in a
high-risk family. Exclusion of a BRCA mutation in one individual
does not necessarily indicate that the family is mutation negative.
As uncontrollable factors such as cost, death and unavailability
often dictate the choice of individual within a family for mutation
testing, it is clear that BRCA mutational status is not a ‘gold
standard test’. Given these limitations in developing and applying
risk models, we advocate the development of risk prediction
models that are less reliant on clinical history.
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